Non-Covalent BTK Inhibitors—The New BTKids on the Block for B-Cell Malignancies

por Lewis, Katharine L, Cheah, Chan Y
Publicado 2021

Marginal zone lymphoma: present status and future perspectives

por Cheah, Chan Y., Zucca, Emanuele, Rossi, Davide, Habermann, Thomas M.
Publicado 2022

A phase 1 clinical trial of the repurposable acetyllysine mimetic, n-methyl-2-pyrrolidone (NMP), in relapsed or refractory multiple myeloma

por Jake Shortt, Galettis, Peter, Cheah, Chan Y., Davis, Joanne, Ludford-Menting, Mandy, Link, Emma K., Martin, Jennifer H., Koldej, Rachel, Ritchie, David
Publicado 2023

P618: LONG-TERM SAFETY WITH ≥12 MONTHS OF PIRTOBRUTINIB IN RELAPSED/REFRACTORY (R/R) B-CELL MALIGNANCIES

por Jurczak, Wojciech, Coombs, Catherine C., Shah, Nirav N., Woyach, Jennifer, Cheah, Chan Y., Patel, Krish, Maddocks, Kami, Wang, Yucai, E. Muehlenbein, Catherine, Wang, Chunxiao, Abhyankar, Sarang, Tsai, Donald E., Eyre, Toby A.
Publicado 2023

Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance

por Blombery, Piers, Thompson, Ella R., Lew, Thomas E., Tiong, Ing Soo, Bennett, Rory, Cheah, Chan Y., Lewis, Katharine Louise, Handunnetti, Sasanka M., Tang, Chloe Pek Sang, Roberts, Andrew, Seymour, John F., Tam, Constantine S.
Publicado 2022

Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma

por Villa, Diego, Jiang, Aixiang, Visco, Carlo, Crosbie, Nicola, McCulloch, Rory, Buege, Michael J., Kumar, Anita, Bond, David A., Paludo, Jonas, Maurer, Matthew J., Thanarajasingam, Gita, Lewis, Katharine L., Cheah, Chan Y., Baech, Joachim, El-Galaly, Tarec C., Kugathasan, Laveniya, Scott, David W., Gerrie, Alina S., Lewis, David
Publicado 2023

P1087: PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS AND SUBGROUP ANALYSIS FROM THE PHASE 1/2 BRUIN STUDY WITH >3 YEARS FOLLOW-UP FROM S...

por Jurczak, Wojciech, Luigi Zinzani, Pier, Eyre, Toby A., Cheah, Chan Y., Ujjani, Chaitra S., Izutsu, Koji, MA, Shuo, Flinn, Ian, Alencar, Alvaro J., Lewis, David, Patel, Krish, Maddocks, Kami, Wang, Yucai, Munir, Talha, Zelenetz, Andrew D., Balbas, Minna, Tsai, Donald E., Wang, Chunxiao, Wang, Michael L., Shah, Nirav N.
Publicado 2023

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

por Thieblemont, Catherine, Phillips, Tycel, Ghesquieres, Herve, Cheah, Chan Y., Clausen, Michael Roost, Cunningham, David, Do, Young Rok, Feldman, Tatyana, Gasiorowski, Robin, Jurczak, Wojciech, Kim, Tae Min, Lewis, David John, van der Poel, Marjolein, Poon, Michelle Limei, Cota Stirner, Mariana, Kilavuz, Nurgul, Chiu, Christopher, Chen, Menghui, Sacchi, Mariana, Elliott, Brian, Ahmadi, Tahamtan, Hutchings, Martin, Lugtenburg, Pieternella J.
Publicado 2023

Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma

por Bartlett, Nancy L., Assouline, Sarit, Giri, Pratyush, Schuster, Stephen J., Cheah, Chan Y., Matasar, Matthew, Gregory, Gareth P., Yoon, Dok Hyun, Shadman, Mazyar, Fay, Keith, Yoon, Sung-Soo, Panizo, Carlos, Flinn, Ian, Johnston, Anna, Bosch, Francesc, Sehn, Laurie H., Wei, Michael C., Yin, Shen, To, Iris, Li, Chi-Chung, Huang, Huang, Kwan, Antonia, Penuel, Elicia, Budde, Lihua E.
Publicado 2023

Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance

por Barraclough, Allison, England, James T., Villa, Diego, Wight, Joel, Hapgood, Greg, Conn, Jason, Doo, Nicole Wong, Li, Eric Wenlong, Gilbertson, Michael, Shaw, Briony, Bishton, Mark J., Saeed, Malik, Ratnasingam, Sumita, Abeyakoon, Chathuri, Chong, Geoff, Wai, Shin Hnin, Ku, Matthew, Lee, Hui-Peng, Fleming, Kathryn, Tam, Constantine, Douglas, Genevieve, Cheah, Chan Y., Ng, Zi Yun, Rolfe, Tukten, Mills, Anthony K., Hamad, Nada, Cashman, Helen, Gleeson, Mary, Narayana, Manjunath, Hawkes, Eliza A.
Publicado 2023

Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma

por Fowler, Nathan H., Samaniego, Felipe, Jurczak, Wojciech, Ghosh, Nilanjan, Derenzini, Enrico, Reeves, James A., Knopińska-Posłuszny, Wanda, Cheah, Chan Y., Phillips, Tycel, Lech-Maranda, Ewa, Cheson, Bruce D., Caimi, Paolo F., Grosicki, Sebastian, Leslie, Lori A., Chavez, Julio C., Fonseca, Gustavo, Babu, Sunil, Hodson, Daniel J., Shao, Spencer H., Burke, John M., Sharman, Jeff P., Law, Jennie Y., Pagel, John M., Miskin, Hari P., Sportelli, Peter, O'Connor, Owen A., Weiss, Michael S., Zinzani, Pier Luigi
Publicado 2021

Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies

por Davids, Matthew S., O’Connor, Owen A., Jurczak, Wojciech, Samaniego, Felipe, Fenske, Timothy S., Zinzani, Pier Luigi, Patel, Manish R., Ghosh, Nilanjan, Cheson, Bruce D., Derenzini, Enrico, Brander, Danielle M., Reeves, James A., Knopińska-Posłuszny, Wanda, Allan, John N., Phillips, Tycel, Caimi, Paolo F., Lech-Maranda, Ewa, Burke, John M., Agajanian, Richy, Pettengell, Ruth, Leslie, Lori A., Cheah, Chan Y., Fonseca, Gustavo, Essell, James, Chavez, Julio C., Pagel, John M., Sharman, Jeff P., Hsu, Yanzhi, Miskin, Hari P., Sportelli, Peter, Weiss, Michael S., Flinn, Ian W.
Publicado 2021

P1108: EFFICACY OF PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA: RESULTS FROM THE PHASE 1/2 BRUIN...

por Scarfò, Lydia, Patel, Manish R., Eyre, Toby A., Jurczak, Wojciech, Lewis, David, Gastinne, Thomas, MA, Shuo, Cohen, Jonathon B., Patel, Krish, Brown, Jennifer R., Munir, Talha, Lech-Maranda, Ewa, Hoffmann, Marc S., Ujjani, Chaitra S., Fakhri, Bita, Wang, Michael, Izutsu, Koji, Nagai, Hirokazu, Tam, Constantine S., Seymour, John F., Rhodes, Joanna, Vose, Julie, Mckinney, Matthew, Gerson, James N., Barve, Minal A., Kuss, Bryone, Koh, Youngil, Gao, Wei, Ruppert, Amy S., Walgren, Richard A., Tsai, Donald E., Nair, Binoj, Bao, Katherine, Mato, Anthony R., Cheah, Chan Y., Lia Palomba, M
Publicado 2023

Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma

por Wang, Michael L., Jurczak, Wojciech, Zinzani, Pier Luigi, Eyre, Toby A., Cheah, Chan Y., Ujjani, Chaitra S., Koh, Youngil, Izutsu, Koji, Gerson, James N., Flinn, Ian, Tessoulin, Benoit, Alencar, Alvaro J., Ma, Shuo, Lewis, David, Lech-Maranda, Ewa, Rhodes, Joanna, Patel, Krish, Maddocks, Kami, Lamanna, Nicole, Wang, Yucai, Tam, Constantine S., Munir, Talha, Nagai, Hirokazu, Hernandez-Ilizaliturri, Francisco, Kumar, Anita, Fenske, Timothy S., Seymour, John F., Zelenetz, Andrew D., Nair, Binoj, Tsai, Donald E., Balbas, Minna, Walgren, Richard A., Abada, Paolo, Wang, Chunxiao, Zhao, Junjie, Mato, Anthony R., Shah, Nirav N.
Publicado 2023